TCA
PGNX

Taconic Capital Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Taconic Capital Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-785,982
Closed -$3.21M – 107
2014
Q1 		$3.21M Hold
785,982
– – 0.13% 63
2013
Q4 		$4.19M Hold
785,982
– – 0.16% 55
2013
Q3 		$3.95M Hold
785,982
– – 0.18% 50
2013
Q2 		$3.5M Buy
+785,982
New +$3.53M 0.13% 59

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Taconic Capital Advisors's PGNX Position: Q2 2014 in Review

Taconic Capital Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2014, closing a stake of 785,982 shares — an estimated $3.21M sold.

Taconic Capital Advisors first reported a position in PGNX in Q2 2013 and held it in 4 quarters. The position peaked at $4.19M in Q4 2013. 76 funds tracked by Wall St. Rank hold PGNX as of Q2 2014.

  • Taconic Capital Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Taconic Capital Advisors sold 785,982 Progenics Pharmaceuticals Inc shares in Q2 2014, an estimated $3.21M.
  • Taconic Capital Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Taconic Capital Advisors's Progenics Pharmaceuticals Inc position peaked at $4.19M in Q4 2013.
  • 76 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2014.

Based on Taconic Capital Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.